In the cutthroat pharmaceutical arena, Pfizer stands poised for a strategic pivot and a potential earnings bonanza in 2025.

Bristol-Myers Squibb unveils its earnings this Thursday. Last quarter, they beat revenue estimates by nearly 4%. Now, ...